CAPRICOR THERAPEUTICS, INC. Proceeds from Notes Payable
CAPRICOR THERAPEUTICS, INC. (CAPR) reported Proceeds from Notes Payable of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-11.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2022-03-11
- CAPRICOR THERAPEUTICS, INC. proceeds from notes payable for the quarter ending 2020-12-31 was $0.00.
- CAPRICOR THERAPEUTICS, INC. proceeds from notes payable for the quarter ending 2020-09-30 was $0.00.
- CAPRICOR THERAPEUTICS, INC. proceeds from notes payable for the quarter ending 2019-12-31 was $0.00.
- CAPRICOR THERAPEUTICS, INC. proceeds from notes payable for the quarter ending 2019-09-30 was $0.00.
- CAPRICOR THERAPEUTICS, INC. proceeds from notes payable for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- CAPRICOR THERAPEUTICS, INC. proceeds from notes payable for fiscal 2020 was $318.16K.
- CAPRICOR THERAPEUTICS, INC. proceeds from notes payable for fiscal 2019 was $0.00.
- CAPRICOR THERAPEUTICS, INC. proceeds from notes payable for fiscal 2012 was $0.00.
| Period end | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 6 month | Proceeds from Notes Payable 9 month | Proceeds from Notes Payable 12 month | Proceeds from Notes Payable 71 month | Proceeds from Notes Payable 74 month | Proceeds from Notes Payable 77 month | Proceeds from Notes Payable 80 month | Proceeds from Notes Payable 83 month | Proceeds from Notes Payable 86 month | Proceeds from Notes Payable 89 month | Proceeds from Notes Payable 92 month | Proceeds from Notes Payable 95 month | Proceeds from Notes Payable 98 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-03-11 | |||||||||||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $0.00 derived: sum of 2 quarters · filed 2022-03-11 | $318.16K 10-K · filed 2022-03-11 | |||||||||||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $318.16K 10-Q · filed 2021-11-12 | ||||||||||||
| 2020-06-30 | $318.16K 10-Q · filed 2021-08-13 | |||||||||||||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | $0.00 derived: sum of 2 quarters · filed 2021-03-15 | $0.00 10-K · filed 2021-03-15 | |||||||||||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | $0.00 10-Q · filed 2020-11-13 | ||||||||||||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-10 | |||||||||||||
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-14 | $0.00 derived: sum of 2 quarters · filed 2013-11-14 | $382.50K 10-Q · filed 2013-11-14 | $382.50K derived: sum of 4 quarters · filed 2013-11-14 | $5.88M 10-Q · filed 2013-11-14 | |||||||||
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-14 | $382.50K 10-Q · filed 2013-08-14 | $382.50K derived: sum of 3 quarters · filed 2013-08-14 | $382.50K derived: sum of 4 quarters · filed 2013-11-14 | $5.88M 10-Q · filed 2013-08-14 | |||||||||
| 2013-03-31 | $382.50K 10-Q · filed 2013-06-21 | $382.50K derived: sum of 2 quarters · filed 2013-06-21 | $382.50K derived: sum of 3 quarters · filed 2013-11-14 | $382.50K derived: sum of 4 quarters · filed 2013-11-14 | $5.88M 10-Q · filed 2013-06-21 | |||||||||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-06-21 | $0.00 derived: sum of 2 quarters · filed 2013-11-14 | $0.00 derived: sum of 3 quarters · filed 2013-11-14 | $0.00 10-K · filed 2013-06-21 | $5.50M 10-K · filed 2013-06-21 | |||||||||
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-14 | $0.00 derived: sum of 2 quarters · filed 2013-11-14 | $0.00 10-Q · filed 2013-11-14 | $0.00 derived: sum of 4 quarters · filed 2013-11-14 | $5.50M 10-Q · filed 2013-06-21 | |||||||||
| 2012-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-14 | $0.00 10-Q · filed 2013-08-14 | $0.00 derived: sum of 3 quarters · filed 2013-08-14 | $5.50M 10-Q/A · filed 2012-09-10 | ||||||||||
| 2012-03-31 | $0.00 10-Q · filed 2013-06-21 | $0.00 derived: sum of 2 quarters · filed 2013-06-21 | $5.50M 10-Q · filed 2012-05-15 | |||||||||||
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-06-21 | $0.00 10-K · filed 2013-06-21 | $5.50M 10-K · filed 2012-04-02 | |||||||||||
| 2011-09-30 | $0.00 10-Q · filed 2013-06-21 | $5.50M 10-Q · filed 2011-11-14 | ||||||||||||
| 2011-06-30 | $5.50M 10-Q · filed 2011-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |